Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564045 | 0.89 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13075166 | 0.80 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL661877 | 0.75 | LMNA (0.54) | LMNACA12CA1CA2CA3 | |
| SCHEMBL12052217 | 0.75 | LMNA (0.40) | LMNACA12CA1CA2CA3 | |
| SCHEMBL660895 | 0.74 | LMNA (0.60) | LMNACA12CA1CA2CA3 | |
| SCHEMBL430450 | 0.73 | LMNA (0.38) | LMNACA12CA1CA2CA3 | |
| SCHEMBL22215214 | 0.72 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28289734 | 0.72 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL30662158 | 0.72 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL3922663 | 0.72 | PTGER4 (0.30) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1993998-B1 | 3-CARBOXY- 2-OXO-1 -PYRROLIDINE DERIVATIVES AND THEIR USES | UCB PHARMA SA (BE) | 2013-08-21 | — | — | EP | disclosed |
| US-20120021469-A1 | AMIDASES AND METHODS OF THEIR USE | CODEXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021469-A1 | AMIDASES AND METHODS OF THEIR USE | CODEXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8076493-B2 | 3-carboxy-2-oxo-1-pyrrolidine derivatives and their uses | UCB PHARMA, S.A. (BE) | 2011-12-13 | — | — | US | disclosed |
| US-8076493-B2 | 3-carboxy-2-oxo-1-pyrrolidine derivatives and their uses | UCB PHARMA, S.A. (BE) | 2011-12-13 | — | — | US | disclosed |
| US-20090012313-A1 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012313-A1 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021469-A1 | AMIDASES AND METHODS OF THEIR USE | ANPEP, DNPEP, NAAA | LMNA 2107/4885CA12 2038/4885CA1 1624/4885 |
| US-20090012313-A1 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses | ALDH18A1, PYCR1, OPRD1 | LMNA 4658/4885CA12 1665/4885CA1 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.